In the context of antibody treatment, NK cells are unique in that they express only the low-affinity activating FcγR CD16 (FcγRIIIA) and no inhibitory receptors, which underscores the significance of antibody-dependent cellular cytotoxicity (ADCC) in eliminating tumor cells [24]. The gene discussed is FCGR2A; the disease is neoplasm.